Peramivir and laninamivir susceptibility of circulating influenza A and B viruses
Version of Record online: 7 NOV 2013
© 2013 The Authors. Influenza and Other Respiratory Viruses Published by John Wiley & Sons Ltd.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
Influenza and Other Respiratory Viruses
Volume 8, Issue 2, pages 135–139, March 2014
How to Cite
2013) Peramivir and laninamivir susceptibility of circulating influenza A and B viruses. Influenza and Other Respiratory Viruses 8(2), 135–139.et al. (
- Issue online: 26 FEB 2014
- Version of Record online: 7 NOV 2013
- Manuscript Accepted: 8 SEP 2013
- Australian NHMRC
- A*STAR Singapore. Grant Number: 12/1/06/24/5793
- Antiviral susceptibility;
- neuraminidase inhibitors;
Influenza viruses collected from regions of Asia, Africa and Oceania between 2009 and 2012 were tested for their susceptibility to two new neuraminidase inhibitors, peramivir and laninamivir. All viruses tested had normal laninamivir inhibition. However, 3·2% (19/599) of A(H1N1)pdm09 viruses had highly reduced peramivir inhibition (due to H275Y NA mutation) and <1% (6/1238) of influenza B viruses had reduced or highly reduced peramivir inhibition, with single occurrence of variants containing I221T, A245T, K360E, A395E, D432G and a combined G145R+Y142H mutation. These data demonstrate that despite an increase in H275Y variants in 2011, there was no marked change in the frequency of peramivir- or laninamivir-resistant variants following the market release of the drugs in Japan in 2010.